Net unrealized (gains)/losses recognized on investments still held Unrealized Gain (Loss) on Investments Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Equity [Line Items] Equity [Line Items] Equity [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Other rebates, returns, discounts and adjustments Other Rebates, Returns, Discounts and Adjustments [Member] Other rebates, returns, discounts and adjustments [Member] Restructuring and related cost, expected cost remaining Restructuring and Related Cost, Expected Cost Remaining Schedule of Short-term Debt Schedule of Short-Term Debt [Table Text Block] Percent of aggregate total trade receivables due from three pharmaceutical wholesalers Percentage Of Aggregate Total Trade Receivables Due The percentage of aggregate trade receivables due from customers accounting for more than 10% of total trade receivables. Award Timing Predetermined Award Timing Predetermined [Flag] Total Intangible Assets, Gross (Excluding Goodwill) Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Unrealized (losses)/gains on marketable debt securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Entity File Number Entity File Number Capital in Excess of Par Value of Stock Additional Paid-in Capital [Member] Interest rate swap contracts Interest Rate Swap [Member] Royalty income - divestitures (Note 4) Business Sale Royalty Income This element represents royalty income recognized in other income during the period related to the sale of a business. Equity in net (income)/loss of affiliates and other adjustments Income (Loss) from Equity Method Investments Performance obligation satisfied in previous period Contract with Customer, Performance Obligation Satisfied in Previous Period OTHER (INCOME)/EXPENSE, NET Other Income and Other Expense Disclosure [Text Block] Contingent value rights Contingent Value Rights [Member] BMY Contingent Value Rights [Member] Acquisitions, Divestitures and Other Arrangements [Abstract] Acquisitions, Divestitures and Other Arrangements [Abstract] Acquisitions, Divestitures and Other Arrangements [Abstract] Tabular List, Table Tabular List [Table Text Block] Other comprehensive income, tax Other Comprehensive Income (Loss), Tax SUPPLEMENTAL FINANCIAL INFORMATION Additional Financial Information Disclosure [Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Medicaid and Medicare rebates Medicaid and Medicare rebates [Member] Medicaid and Medicare rebates [Member] Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Machinery, equipment and fixtures Machinery and Equipment, Gross Net Proceeds Proceeds from Divestiture of Businesses, Net of Cash Divested FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Divestitures Disposal Groups, Including Discontinued Operations [Table Text Block] Type of Restructuring [Domain] Type of Restructuring [Domain] Acquired IPRD Acquired IPRD Acquired IPRD Equity [Table] Equity [Table] Equity Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Recognized in Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Total inventories Inventory, Gross Commercial paper Commercial Paper [Member] REVENUE Revenue from Contract with Customer [Text Block] Selected Financial Information For Alliances Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Research Other Research [Member] Other Research Total other comprehensive income/(loss) Other comprehensive income/(loss) Other Comprehensive Income (Loss), Net of Tax Other revenues Other Revenues [Member] Other revenues [Member] Short-term debt obligations Short-Term Debt Other Other Assets, Miscellaneous, Noncurrent Adjustment to Compensation, Amount Adjustment to Compensation Amount Basis of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Employee Stock Option Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Income taxes Prepaid Taxes Foreign currency translation, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Rebates and discounts Accrued Rebates And Returns Carrying value as of the balance sheet date of obligations incurred and payable pertaining to rebates to government programs and sales returns. Recognized in other comprehensive income/(loss), tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Cash dividends declared Dividends, Common Stock, Cash Total BMS Shareholders’ equity Equity, Attributable to Parent Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other comprehensive income/(loss), net of taxes and reclassifications to earnings: Other Comprehensive Income (Loss), Net of Tax [Abstract] Insider Trading Policies and Procedures [Line Items] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Licensing and Other Arrangements [Domain] Licensing and Other Arrangements [Domain] Licensing and Other Arrangements Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current assets: Assets, Current [Abstract] Total Liabilities and Equity Liabilities and Equity Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Equity investments (Note 9) Equity Investments, Noncurrent Equity Investments, Noncurrent Camzyos Camzyos [Member] Camzyos Other shutdown costs, net Other Shutdown Costs [Member] Other Shutdown Costs Other Nonoperating Income (Expense) [Abstract] Other Nonoperating Income (Expense) [Abstract] Cover [Abstract] Money market and other securities Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] Estimated useful lives (in years) Finite-Lived Intangible Asset, Useful Life Actuarial gains/(losses), tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax Accounting Policies [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Treasury Stock Treasury Stock, Common [Member] Impairments and downward adjustments Equity Securities without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Annual Amount Equity Securities without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Annual Amount Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Foreign Currency Fair Value Hedge Derivative [Line Items] Foreign Currency Fair Value Hedge Derivative [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Equity investments Other Assets [Member] LIABILITIES Liabilities [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Earnings/(Loss) before income taxes Earnings/(Loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Other non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Schedule of Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Recognized in other comprehensive income/(loss), after tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Current portion of Long-term debt Long-Term Debt, Current Maturities Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Noncontrolling interest Comprehensive income/(loss) attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Derivatives qualifying as cash flow hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Comprehensive income/(loss) attributable to BMS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Disposal Group Name [Domain] Disposal Group Name [Domain] Name Measure Name Beginning balance Ending balance Restructuring Reserve Income taxes Accrued Income Taxes, Noncurrent Reblozyl License Reblozyl License [Member] Reblozyl License Alliance, royalties, VAT and other Other Receivables Operating leases Operating Lease, Liability, Current Deferred income taxes Deferred Income Tax Liabilities, Net Document Fiscal Period Focus Document Fiscal Period Focus Licensing Arrangements [Table] Licensing Arrangements [Table] Licensing Arrangements [Table] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Renewal period (in years) Long-term Debt, Renewal Period Long-term Debt, Renewal Period Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] Other revenue Other Revenue, Hedging Activities [Member] Other Revenue, Hedging Activities Acquired marketed product rights Acquired Marketed Product Rights [Member] Acquired Marketed Product Rights Award Type [Axis] Award Type [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Total Long-Term Debt Schedule of Comprehensive Income Loss Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Alliance Statement [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Other termination costs Other Termination Costs [Member] Other Termination Costs Trading Symbol Trading Symbol Pension and postretirement benefits Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Revlimid Revlimid [Member] Revlimid [Member] Japan, Yen Japan, Yen Geographical [Domain] Geographical [Domain] Schedule of Other Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Entity Address, City or Town Entity Address, City or Town Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Total GTN adjustments Gross to Net Adjustments Gross to Net Adjustments Cash Flows From Operating Activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Foreign currency translation, pretax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Effect of exchange rates on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Concentration Risk Type [Axis] Concentration Risk Type [Axis] INVENTORIES Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Employee termination costs Severance Costs Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Dividends declared (in usd per share) Common Stock, Dividends, Per Share, Declared Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule Of Other Income Expense Schedule Of Other Income Expense [Table Text Block] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Non-U.S. short-term financing obligations Short-Term Bank Loans and Notes Payable Net investment hedge gains Derivatives used in Net Investment Hedge, Net of Tax Level 2 Fair Value, Inputs, Level 2 [Member] Gain (loss) on derivative, net Derivative, Gain (Loss) on Derivative, Net 3.363% Notes due 2033 3.363% Notes due 2033 [Member] 3.363% Notes due 2033 Limited partnerships and other investments Equity Method Investments Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] IPRD Indefinite-Lived Intangible Assets (Excluding Goodwill) Divestiture (Gains)/Losses Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Gross product sales Sales Revenue, Gross [Member] Sales Revenue, Gross [Member] Breyanzi Breyanzi [Member] Breyanzi PEO PEO [Member] Other Acquisition Plans Celgene and Other Acquisition Plans [Member] Celgene and Other Acquisition Plans RECEIVABLES Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Investment income Investment Income, Interest Pension and postretirement Assets for Plan Benefits, Defined Benefit Plan Income taxes Accrued Income Taxes, Current United States UNITED STATES Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Gross to Net Adjustments [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Retained Earnings Retained Earnings [Member] Other Growth products Other Growth Brands [Member] Other Growth Brands Schedule of Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-Based Payment Arrangement [Abstract] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Derivative assets Derivative Asset Income tax provision Income Tax Expense (Benefit) Cobenfy Cobenfy [Member] Cobenfy Celgene Contingent Value Rights Celgene Contingent Value Rights [Member] Celgene Contingent Value Rights [Member] Purchase of marketable debt securities Payments to Acquire Marketable Securities Derivatives qualifying as cash flow hedges, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Other intangible assets Other intangible assets Intangible Assets, Net (Excluding Goodwill) Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Designated as cash flow hedges Designated as Hedging Instrument [Member] Percentage of net sales payable to alliance partner Percentage Of Net Sales Payable To Alliance Partner Percentage Of Net Sales Payable To Alliance Partner Product and Service [Domain] Product and Service [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Yervoy Yervoy [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Derivatives qualifying as cash flow hedges Derivatives qualifying as cash flow hedges, after tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Gross property, plant and equipment Property, Plant and Equipment, Gross Net earnings/(loss) Net earnings/(loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Marketable debt securities AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Derivative, notional amount Derivative, Notional Amount Actuarial gains/(losses), after tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Gross to Net Adjustments [Axis] Gross to Net Adjustments [Axis] Gross to Net Adjustments [Axis] Sotyktu Sotyktu [Member] Sotyktu RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS Mergers, Acquisitions and Dispositions Disclosures [Text Block] Acquisition and other payments, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Litigation and other settlements Gain (Loss) from Litigation Settlement Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Buildings Buildings and Improvements, Gross Debt instrument, maximum amount authorized for issuance Commercial Paper, Maximum Aggregate Capacity Commercial Paper, Maximum Aggregate Capacity Cash Flows From Investing Activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Debt instrument, term Debt Instrument, Term ALLIANCES [Abstract] ALLIANCES [Abstract] ALLIANCES [Abstract] Selling, general and administrative Selling, General and Administrative Expenses [Member] Cash Flow Hedging Cash Flow Hedging [Member] Cost of products sold (Gains)/losses recognized in Cost of products sold Cost of Sales [Member] Goodwill Balance at December 31, 2025 Balance at March 31, 2026 Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Royalty Income Royalty Income, Income From Divestiture Royalty Income, Income From Divestiture PEO Total Compensation Amount PEO Total Compensation Amount Settlements, pretax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Depreciation expense Depreciation Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Equity investment (gains)/losses, net (Note 9) Total equity investment (gains)/losses Gain (Loss) on Investments Divestiture gains and royalties Divestiture Gains And Royalties This represents the amount of gains and royalties as a result of business divestitures. Derivatives designated as net investment hedges Summary of Net Investment Hedge Activity [Abstract] Equity Components [Axis] Equity Components [Axis] International Non-US [Member] Prior period gross to net adjustment impacted by new accounting pronouncement Prior Period Gross to Net Adjustment, Decrease (Increase) From Change in Estimate Prior Period Gross to Net Adjustment, Decrease (Increase) From Change in Estimate Revenue Recognition Gross-To-Net Adjustments Reconciliation of Gross Product Sales to Net Product Sales [Table Text Block] Reconciliation of Gross Product Sales to Net Product Sales [Table Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk [Table] Concentration Risk [Table] Supplemental Financial Information [Abstract] Supplemental Financial Information [Abstract] Supplemental Financial Information [Abstract] Amortization, after tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Research and development Accrued Research And Development Carrying value as of the balance sheet date of obligations and payables pertaining to research and development. Other termination costs Other Restructuring Costs Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Short-term debt obligations Debt, Current Foreign currency translation Foreign currency translation, after tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Entity Address, State or Province Entity Address, State or Province Euro Member Countries, Euro Euro Member Countries, Euro Total Current liabilities Liabilities, Current Earnings/(Loss) per common share Earnings Per Share, Basic and Diluted EPS [Abstract] Earnings Per Share, Basic and Diluted EPS Derivative Instrument [Axis] Derivative Instrument [Axis] Restructuring and related cost, cost incurred to date Restructuring and Related Cost, Cost Incurred to Date Schedule of Research and Development Expense [Table] Schedule of Research and Development Expense [Table] Schedule of Research and Development Expense Individual: Individual [Axis] Drug Development Drug Development [Member] Drug Development Settlements, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax Other current assets Other current assets Other Assets, Current Floating rate notes due 2026 Floating Rate Notes Due 2026 [Member] Floating Rate Notes Due 2026 Research and development Research and Development Expense [Member] Equity investments without RDFV Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Cumulative impairment amount Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Licensing Arrangements [Line Items] Licensing Arrangements [Line Items] Licensing Arrangements Net cash provided by/(used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest payments Interest Paid, Excluding Capitalized Interest, Operating Activity Document Fiscal Year Focus Document Fiscal Year Focus Operating leases Operating Lease, Right-of-Use Asset Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Repayments of long-term debt Repayments of Long-Term Debt Effective tax rate Effective Income Tax Rate Reconciliation, Percent Entity Interactive Data Current Entity Interactive Data Current Capitalized software Computer Software, Intangible Asset [Member] Expected weighted-average period in years of compensation cost to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Licensing and Other Arrangements Licensing and Other Arrangements [Table Text Block] Licensing and Other Arrangements LEGAL PROCEEDINGS AND CONTINGENCIES Legal Matters and Contingencies [Text Block] Equity [Abstract] Equity [Abstract] Cumulative upward adjustments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Not designated as hedges Not Designated as Hedging Instrument [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. Treasury securities US Treasury Securities [Member] Tecentriq royalties Tecentriq royalties [Member] Tecentriq royalties Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other intangible assets Finite-Lived Intangible Assets [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Contingent value rights Business Combination, Contingent Consideration, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortization of intangible assets Amortization of Intangible Assets Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Deferred income taxes Deferred Income Tax Assets, Net Schedule of Accumulated Other Comprehensive Income Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Depreciation and amortization, net Depreciation, Depletion and Amortization Share-based Payment Arrangement, Nonvested Award, Cost Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Other non-current assets Other non-current assets Other Assets, Noncurrent Royalties Accrued Royalties, Current Interest Interest Payable, Current Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Foreign currency translation Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Intangible Asset Name [Axis] Intangible Asset Name [Axis] Intangible Asset Name Total Revenues Total alliance revenues Revenues Common Stock $0.10 Par Value Common Stock $0.10 Par Value [Member] CommonStock010ParValueMember Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Other Legacy products Other Legacy Brands [Member] Other Legacy Brands Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Putative claims Loss Contingency, Pending Claims, Number, Putative Class Loss Contingency, Pending Claims, Number, Punitive Class Schedule of Stock by Class Schedule of Stockholders Equity [Table Text Block] Revolving Credit Facility Revolving Credit Facility [Member] 4.581% Notes due 2055 4.581% Notes due 2055 [Member] 4.581% Notes due 2055 Arrangement Duration Trading Arrangement Duration Debt Securities, Trading, and Equity Securities, FV-NI Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Schedule of Derivatives and Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Work in process Inventory, Work in Process, Net of Reserves Write-Down Of Radiopharmaceutical Asset Write-Down Of Radiopharmaceutical Asset [Member] Write-Down Of Radiopharmaceutical Asset Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Class of Stock [Domain] Class of Stock [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Trade receivables Accounts Receivable, before Allowance for Credit Loss, Current Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Provision for restructuring Restructuring Charges Excluding Accelerated Stock-based Compensation Restructuring Charges Excluding Accelerated Stock-based Compensation EMPLOYEE STOCK BENEFIT PLANS Share-Based Payment Arrangement [Text Block] Liability Liability [Member] Expected restructuring and related charges Restructuring and Related Cost, Expected Cost Royalty and licensing income Licensing And Other Arrangements Income Licensing And Other Arrangements Income ASSETS Assets [Abstract] Proceeds from royalties received Proceeds from Royalties Received Long-term debt Long-Term Debt, Excluding Current Maturities Unrealized (losses)/gains on marketable debt securities, pretax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax Other non-current assets Inventories (Note 12) Inventory, Noncurrent Credit Facility [Axis] Credit Facility [Axis] Total return swap contracts Other Contract [Member] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Gross to Net Adjustments [Domain] Gross to Net Adjustments [Domain] [Domain] for Gross to Net Adjustments [Axis] Debt Instrument [Axis] Debt Instrument [Axis] Gross carrying amounts Finite-Lived Intangible Assets, Gross Credit Facility [Domain] Credit Facility [Domain] BMS Shareholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] 2.973% Notes due 2030 2.973% Notes due 2030 [Member] 2.973% Notes due 2030 Research and development Research and Development, Noncurrent Research and Development, Noncurrent $5.0 Billion Maximum Borrowing Capacity $5.0 Billion Maximum Borrowing Capacity [Member] $5.0 Billion Maximum Borrowing Capacity Entity Address, Address Line One Entity Address, Address Line One Research and development Research and Development Expense Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Less allowance for expected credit loss Accounts Receivable, Allowance for Credit Loss, Current Keytruda royalties Keytruda Royalties [Member] Keytruda Royalties Revenue from External Customers by Products and Services Revenue from External Customers by Products and Services [Table Text Block] Market share units Market Share Units [Member] Stock compensation (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Operating leases Operating Lease, Liability, Noncurrent 3.857% Notes due 2038 3.857% Notes due 2038 [Member] 3.857% Notes due 2038 Amortization of deferred income Amortization Of Deferred Income Amortization Of Deferred Income Royalty expense Royalty Expense 4.289% Notes due 2045 4.289% Notes due 2045 [Member] 4.289% Notes due 2045 Marketable debt securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax [Abstract] Land Land Asset impairments Restructuring, Settlement and Impairment Provisions Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Reclassified to net earnings, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Net realized (gains)/losses recognized on investments sold Equity Securities without Readily Determinable Fair Value, Realized Gain (Loss) Equity Securities without Readily Determinable Fair Value, Realized Gain (Loss) Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Pre-tax gains Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Collaborative Arrangement Collaborative Arrangement [Member] Amortization of acquired intangible assets Amortization of Acquired Intangible Assets Amortization of Acquired Intangible Assets Nature of Expense [Axis] Nature of Expense [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Deferred compensation Deferred Compensation Liability, Classified, Noncurrent Schedule of Long-term Debt and Current Portion of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Incremental shares attributable to share-based compensation plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Number of units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total Expenses Costs and Expenses Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Krazati Krazati [Member] Krazati Contingent value rights (Note 9) Contingent Value Rights, Noncurrent Contingent Value Rights, Noncurrent Opdivo Qvantig Opdivo Ovantig [Member] Opdivo Ovantig Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Equity investments without RDFV Equity Securities without Readily Determinable Fair Value, Amount Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] (Gains)/losses recognized in Other (income)/expense, net (Gains)/losses recognized in Other (income)/expense, net Other Income [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Weighted-average fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Payment and royalty allocation Payment And Royalty Allocation Payment And Royalty Allocation Litigation [Table] Litigation [Table] Amortization, pretax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Impairment charges Impairment of Long-Lived Assets to be Disposed of Stock compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Currency [Domain] All Currencies [Domain] Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] Deferred income – from alliances Deferred Income Derivatives qualifying as cash flow hedges, pretax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Recognized in Other comprehensive income/(loss) Recognized in other comprehensive income/(loss), pretax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other royalties and licensing income Other Royalties and Licensing Income [Member] Other Royalties and Licensing Income Divestiture and other proceeds Divestiture And Other Proceeds This element represents the cash inflow during the period from the sale of a business, asset or other proceeds. Noncontrolling interest Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Other adjustments Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Principal value Debt Instrument, Face Amount Pension and postretirement benefits, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Schedule of Provision for Income Taxes Schedule of Provision for Income Taxes [Table Text Block] -- None. No documentation exists for this element. -- Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Foreign currency exchange contracts Foreign Exchange Contract [Member] Certificates of deposit Certificates of Deposit [Member] Gross to Net Adjustments [Line Items] Gross to Net Adjustments [Line Items] [Line Items] for Gross to Net Adjustments [Table] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name Payments Payments for Restructuring Derivatives qualifying as cash flow hedges AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Restructuring Type [Axis] Restructuring Type [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other Other Accrued Liabilities, Noncurrent Other short-term financing obligations, net Proceeds from Other Short-Term Debt Winrevair* License Winrevair* License [Member] Winrevair* License IPRD In Process Research and Development [Member] Accumulated other comprehensive loss Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Celgene Securities Class Action Celgene Securities Class Action [Member] Celgene Securities Class Action Unamortized basis adjustment from swap terminations Unamortized Basis Adjustment From Swap Terminations This element represents the adjustment to principal value of long term debt related to the unamortized basis adjustment from swap terminations. Financial Instruments [Domain] Financial Instruments [Domain] Marketable debt securities Unrealized (losses)/gains on marketable debt securities, after tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Litigation Case [Axis] Litigation Case [Axis] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Performance share units Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Reclassified to net earnings, after tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Inventories Increase (Decrease) in Inventories Inventories Inventory, Net Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Licensing and Other Arrangements [Axis] Licensing and Other Arrangements [Axis] Licensing and Other Arrangements Minimum Minimum [Member] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Limited partnerships and other investments Limited Partnerships and Other Equity Method Investments [Abstract] Limited Partnerships and Other Equity Method Investments Account Receivables [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Company Selected Measure Name Company Selected Measure Name Intangible Asset Name [Domain] Intangible Asset Name [Domain] Intangible Asset Name [Domain] Three Customers Three Customers [Member] Three Customers FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Preferred stock Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts payable – to alliance partners Accounts Payable, Current Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other comprehensive income, pre-tax Other Comprehensive Income (Loss), before Tax Assets Assets [Member] All Executive Categories All Executive Categories [Member] Finished goods Inventory, Finished Goods, Net of Reserves Goodwill [Roll Forward] Goodwill [Roll Forward] Restructuring Plan [Domain] Restructuring Plan [Domain] Settlements, after tax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax Weighted-average common shares outstanding – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Pomalyst/Imnovid Pomalyst/Imnovid [Member] Pomalyst/Imnovid [Member] Integration expenses (Note 6) Integration expenses Business Combination, Integration-Related Cost, Expense Business Segment Information Segment Reporting, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Amortization, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Raw and packaging materials Inventory, Raw Materials and Supplies, Net of Reserves Comprehensive income/(loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Other Other Prepaid Expense, Current Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Research and development Research and Development, Current Research and Development, Current Noncontrolling Interest Noncontrolling Interest [Member] Document Transition Report Document Transition Report Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Alliance and other revenues Gains/(losses) recognized in Alliance and other revenues Alliance And Other Revenues [Member] Alliance And Other Revenues Document Period End Date Document Period End Date Ono Ono [Member] Ono PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term debt, term (in years) Long-Term Debt, Term INCOME TAXES Income Tax Disclosure [Text Block] Unamortized purchase price adjustments of Celgene debt Debt Instrument, Unamortized Premium Obligation to holders of the contingent value rights Contractual Obligation Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Hedging Designation [Axis] Hedging Designation [Axis] Long-term debt, fair value Debt Instrument, Fair Value Disclosure Scenario [Axis] Scenario [Axis] 1.750% Notes due 2035 1.750% Notes due 2035 [Member] One750NotesDue2035Member Total Equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Foreign currency exchange contracts gains/(losses): Foreign Currency Derivatives [Abstract] Schedule of Equity Investments Schedule of Equity Investments [Table Text Block] Schedule of Equity Investments Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] EARNINGS/(LOSS) PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Capital in excess of par value of stock Additional Paid in Capital Pension and postretirement benefits Pension and postretirement benefits, after tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Product and Service [Axis] Product and Service [Axis] Reclassified to net earnings, pretax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Net Investment Hedging Net Investment Hedging [Member] Derivative Contract [Domain] Derivative Contract [Domain] Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Derivatives designated as cash flow hedges General Cash Flow Hedge Information [Abstract] Legal Proceedings and Contingencies [Line Items] Legal Proceedings And Contingencies [Line Items] All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Receivables Increase (Decrease) in Receivables Capital expenditures Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Total Current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Stock option proceeds and other, net Payments For (Proceeds From) Stock Option Exercises And Other Adjustments Payments For (Proceeds From) Stock Option Exercises And Other Adjustments Equity investment (gains)/losses, net Equity Method Investment, Realized Gain (Loss) on Disposal Less charge-backs and cash discounts Cash Discounts The amount of reductions to trade receivables incurred during the period attributable to cash discounts. Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Royalty and licensing income (Note 4) Other Income Received From Alliance Partners This element represents the amount of other income received during the period related to alliance partners and includes the amortization of milestone payments received and royalty income. Disposal Group Name [Axis] Disposal Group Name [Axis] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Debt securities, available-for-sale, term Debt Securities, Available-for-Sale, Term Current liabilities: Liabilities, Current [Abstract] 2023 Restructuring Plan 2023 Restructuring Plan [Member] 2023 Restructuring Plan Geographical [Axis] Geographical [Axis] Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Borrowings outstanding Long-Term Line of Credit Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Research and Development Expense [Line Items] Schedule of Research and Development Expense [Line Items] Schedule of Research and Development Expense Opdivo Opdivo [Member] Diluted (usd per share) Earnings Per Share, Diluted Forecast Forecast [Member] Other Research and Development Expense, Other [Member] Research and Development Expense, Other Rebates and discounts Increase (Decrease) in Other Accrued Liabilities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Net trade receivables Accounts Receivable, after Allowance for Credit Loss, Current Commercial Paper Program Commercial Paper Program [Member] Commercial Paper Program Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Title of 12(b) Security Title of 12(b) Security Legacy Portfolio Legacy Brands [Member] Legacy Brands Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Opdualag Opdualag [Member] Opdualag Diabetes business - royalties Diabetes Business [Member] Diabetes business [Member] Net product sales Net Product Sales [Member] Net product sales [Member] Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Earnings/(Loss) per common share: Earnings Per Share [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Marketable debt securities Debt Securities, Available-for-Sale, Current Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Mature products and other Mature Brands and Other [Member] Mature Brands and Other Sprycel Sprycel [Member] Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Proceeds from sales of equity investments Proceeds from Sale of Equity Securities, FV-NI Actuarial gains/(losses), pretax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Debt repaid, principal Debt Instrument, Repaid, Principal Income tax payments Income Taxes Paid, Net Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Award Timing Disclosures [Line Items] Accrued liabilities for CERCLA matters Accrued Liabilities Inventories Schedule of Inventory, Current [Table Text Block] Employee compensation and benefits Employee-related Liabilities, Current Foreign currency translation and other Restructuring Reserve, Foreign Currency Translation Gain (Loss) PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Foreign Currency Fair Value Hedge Derivative [Table] Foreign Currency Fair Value Hedge Derivative [Table] EQUITY Equity [Text Block] Other Other Income Expense The net amount of other (income)/expense which does not qualify for separate disclosure under materiality guidelines. Pension and postretirement benefits, pre-tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Net earnings/(loss) attributable to BMS Net earnings/(loss) attributable to BMS Net Income (Loss) Attributable to Parent Expiration Date Trading Arrangement Expiration Date Other Other Accrued Liabilities, Current EQUITY Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Net (gains)/losses recognized Equity Securities, FV-NI, Unrealized Gain (Loss) Property, plant and equipment Property, plant and equipment Property, Plant and Equipment, Net Provision for restructuring (Note 6) Provision for restructuring Restructuring Charges Royalty income, nonoperating Royalty Income, Nonoperating Adoption Date Trading Arrangement Adoption Date Schedule of Research and Development Research and Development [Table Text Block] Research and Development Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Entity Current Reporting Status Entity Current Reporting Status Total equity investments Equity Investments Equity Investments Derivative [Line Items] Derivative [Line Items] Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Line of Credit Line of Credit [Member] Retained earnings Retained Earnings (Accumulated Deficit) Deferred income Deferred Income, Noncurrent Cross-currency swap contracts Cross Currency Interest Rate Contract [Member] Share-based Payment Arrangement, Cost by Plan Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Foreign currency exchange contracts Foreign Exchange Forward [Member] Orencia Orencia [Member] IPRD impairment charge Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Current Fiscal Year End Date Current Fiscal Year End Date Class of Stock [Axis] Class of Stock [Axis] R&D technology Technology-Based Intangible Assets [Member] Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of Receivables Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Other (income)/expense, net Other (income)/expense, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Derivative liabilities Fair value of interest rate swap contracts Derivative Liability Deferred income taxes Deferred Income Tax Expense (Benefit) Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] ALLIANCES Collaborative Arrangement Disclosure [Text Block] Cash Flows From Financing Activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Alliance revenues Alliance Revenues [Member] Alliance Revenues Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Forward interest rate contracts Interest Rate Contract [Member] Eliquis Eliquis [Member] Accounts Receivable, after Allowance for Credit Loss [Abstract] Accounts Receivable, after Allowance for Credit Loss [Abstract] Receivables Receivables – from alliance partners Receivables Receivables, Net, Current Cross-currency swap contracts Cross Currency Swap Contracts [Member] Cross Currency Swap Contracts Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Equity investments Equity investments with RDFV Equity Securities, FV-NI, Current Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Less cost of treasury stock Treasury Stock, Common, Value Termination Date Trading Arrangement Termination Date Net cash provided by/(used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Pension and postretirement benefits Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract] $5 Billion Maximum Borrowing Capacity $5 Billion Maximum Borrowing Capacity [Member] $5 Billion Maximum Borrowing Capacity Marketable debt securities Debt Securities, Available-for-Sale, Noncurrent Reblozyl Reblozyl [Member] Reblozyl [Member] Currency translation and other adjustments Goodwill, Foreign Currency Translation and Measurement Period Adjustments Weighted-average common shares outstanding – basic (in shares) Weighted Average Number of Shares Outstanding, Basic Cost of products sold Cost of Product and Service Sold Schedule of Earnings/(Loss) Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-U.S. receivables sold on a nonrecourse basis Receivables Sold On Nonrecourse Basis The amount of receivables sold on a nonrecourse basis during the year. Merck Merck [Member] Merck Schedule of Share-based Compensation Additional Information Schedule Of Share Based Compensation Additional Information [Table Text Block] Tabular disclosure of the total intrinsic value of options exercised (or share units converted), total fair value of shares vested during the year and the weighted-average grant-date fair value of equity options or other equity instruments granted during the year. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Scenario [Domain] Scenario [Domain] Abraxane Abraxane [Member] Abraxane [Member] Charge-backs and cash discounts Charge-backs and cash discounts [Member] Charge-backs and cash discounts [Member] Zeposia Zeposia [Member] Zeposia Unamortized bond discounts and issuance costs Debt Instrument, Unamortized Discount Inventory, Net [Abstract] Inventory, Net [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Less: net (gains)/losses recognized on investments sold Equity Securities, FV-NI, Realized Gain (Loss) GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Growth Portfolio Growth Brands [Member] Growth Brands Use of Estimates and Judgments Use of Estimates, Policy [Policy Text Block] Dividends Dividends Payable, Current Dividends Payments of Dividends Construction in progress Construction in Progress, Gross Interest expense Interest Expense, Nonoperating Schedule of Goodwill Schedule of Goodwill [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] Income taxes payable Increase (Decrease) in Income Taxes Payable Total Shareholder Return Amount Total Shareholder Return Amount Schedule of Other Assets, Noncurrent Schedule of Other Assets, Noncurrent [Table Text Block] Upward adjustments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Total charges Restructuring Costs and Asset Impairment Charges Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Equity investments with RDFV Equity Securities, FV-NI [Abstract] Total Liabilities Liabilities Currency [Axis] Currency [Axis] Other (income)/expense, net Other Nonoperating Income (Expense) [Member] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Common stock Common Stock, Value, Outstanding Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Sale and maturities of marketable debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other current liabilities Other current liabilities Other Liabilities, Current Contingent milestone income Contingent Regulatory Milestone Income Contingent Regulatory Milestone Income Pension and postretirement Liability, Defined Benefit Plan, Noncurrent Statement [Line Items] Statement [Line Items] Other Other Region [Member] Schedule of Restructuring Reserve by Type of Cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Research and development Research and Development Expense, Collaborative Arrangement Research and Development Expense - Collaborative Arrangement. The balance can be debit/credit based on the nature of the arrangement. Common Stock Common Stock [Member] Marketable debt securities Debt Securities, Available-for-Sale Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring Charges [Abstract] Restructuring Charges [Abstract] Non-NEOs Non-NEOs [Member] Corporate debt securities Corporate Debt Securities [Member] Increase/(decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation